Skip to main content
Premium Trial:

Request an Annual Quote

Gerald Cox, Kenneth LeClair, and Semiramis Trotto

Editas Medicine has expanded its senior management team by appointing Gerald Cox as chief medical officer, Kenneth LeClair as vice president of technical development and manufacturing, and Semiramis Trotto as vice president of human resources. Cox has held senior clinical development roles at Sanofi Genzyme (formerly Genzyme) for over 15 years. He most recently served as vice president of rare disease clinical development at Sanofi Genzyme. Cox also continues to serve in a part-time role as staff physician in genetics at Boston Children's Hospital. LeClair joins Editas from Novartis Pharmaceuticals, where he served as executive director of technical research and development of the cell and gene therapies unit. He has also worked as a postdoctoral research fellow at the MIT Center for Cancer Research and as an assistant professor of medicine at the Beth Israel Deaconess Medical Center at Harvard Medical School. Trotto comes to Editas from Baxalta, where she most recently served as the vice president of human resources in oncology. Before her time at Baxalta she spent over a decade at Bristol-Myers Squibb where she was responsible for human resources across a number of different business function in the US and internationally.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.